Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Immunome Analyst Ratings and Price Targets | NASDAQ:IMNM | Benzinga
Immunome Inc has a consensus price target of $21.33 based on the ratings of 9 analysts. The high is $33 issued by Wedbush on March 20, 2025. The low is $8 issued by Cantor Fitzgerald on March 20, 2023. The 3 most-recent analyst ratings were released by Lake Street, Wedbush, and Stephens & Co. on April 2, 2025, March 20, 2025, and March 20, 2025, respectively. With an average price target of $28.67 between Lake Street, Wedbush, and Stephens & Co., there's an implied 265.65% upside for Immunome Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Lake Street
Wedbush
Stephens & Co.
Guggenheim
LifeSci Capital
1calculated from analyst ratings
Analyst Ratings for Immunome
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/02/2025 | Buy Now | 193.37% | Lake Street | Chad Messer13% | → $23 | Initiates | → Buy | Get Alert |
| 03/20/2025 | Buy Now | 320.92% | Wedbush | David Nierengarten65% | $33 → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 03/20/2025 | Buy Now | 282.65% | Stephens & Co. | Sudan Loganathan17% | $30 → $30 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2025 | Buy Now | 218.88% | Guggenheim | Michael Schmidt43% | $35 → $25 | Maintains | Buy | Get Alert |
| 03/11/2025 | Buy Now | 155.1% | LifeSci Capital | — | → $20 | Initiates | → Outperform | Get Alert |
| 11/14/2024 | Buy Now | 167.86% | Piper Sandler | Biren Amin34% | $23 → $21 | Maintains | Overweight | Get Alert |
| 11/08/2024 | Buy Now | 282.65% | Stephens & Co. | Sudan Loganathan17% | → $30 | Initiates | → Overweight | Get Alert |
| 10/25/2024 | Buy Now | 320.92% | Wedbush | David Nierengarten65% | $33 → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 08/13/2024 | Buy Now | 193.37% | Piper Sandler | Biren Amin34% | $27 → $23 | Maintains | Overweight | Get Alert |
| 08/13/2024 | Buy Now | 320.92% | Wedbush | David Nierengarten65% | $33 → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 05/31/2024 | Buy Now | 244.39% | Piper Sandler | Biren Amin34% | → $27 | Initiates | → Overweight | Get Alert |
| 04/30/2024 | Buy Now | 206.12% | JP Morgan | Brian Cheng37% | → $24 | Initiates | → Overweight | Get Alert |
| 04/15/2024 | Buy Now | 346.43% | Guggenheim | Michael Schmidt43% | → $35 | Initiates | → Buy | Get Alert |
| 04/01/2024 | Buy Now | 320.92% | Wedbush | David Nierengarten65% | $27 → $33 | Maintains | Outperform | Get Alert |
| 01/23/2024 | Buy Now | 142.35% | Wedbush | David Nierengarten65% | $12 → $19 | Maintains | Outperform | Get Alert |
| 12/19/2023 | Buy Now | 53.06% | Wedbush | David Nierengarten65% | → $12 | Initiates | → Outperform | Get Alert |
| 03/20/2023 | Buy Now | 2.04% | Cantor Fitzgerald | Pete Stavropoulos39% | → $8 | Reiterates | → Overweight | Get Alert |
| 03/17/2023 | Buy Now | 2.04% | Chardan Capital | Matthew Barcus72% | $9 → $8 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Immunome (IMNM) stock?
The latest price target for Immunome (NASDAQ:IMNM) was reported by Lake Street on April 2, 2025. The analyst firm set a price target for $23.00 expecting IMNM to rise to within 12 months (a possible 193.37% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunome (IMNM)?
The latest analyst rating for Immunome (NASDAQ:IMNM) was provided by Lake Street, and Immunome initiated their buy rating.
When was the last upgrade for Immunome (IMNM)?
There is no last upgrade for Immunome
When was the last downgrade for Immunome (IMNM)?
There is no last downgrade for Immunome.
When is the next analyst rating going to be posted or updated for Immunome (IMNM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunome, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunome was filed on April 2, 2025 so you should expect the next rating to be made available sometime around April 2, 2026.
Is the Analyst Rating Immunome (IMNM) correct?
While ratings are subjective and will change, the latest Immunome (IMNM) rating was a initiated with a price target of $0.00 to $23.00. The current price Immunome (IMNM) is trading at is $7.84, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
